FinancingMystery solved: Mysthera Theapeutics launches with $3.5mMysthera Therapeutics AG has launched in Basel with $3.5m in seed funding from founding investor Forty51 Ventures. The capital will be used to advance its preclinical portfolio in a variety of autoimmune … more ➔
financingMithra raises €20m through private placementWomen’s health specialist Mithra Pharmaceuticals SA has entered into a definitive agreement to raise €20m in gross proceeds via a private placement of 10 million new ordinary shares with Armistice … more ➔
AMRDutch researchers and Novobiotics Inc present weapon vs AMRResearchers at the Universities of Bonn (Germany) and Utrecht (The Netherlands and from NovoBiotic Pharmaceuticals (Cambridge, US) have discovered a new class of antibiotics. They isolated clovibactin … more ➔
BiomanufacturingUK invests in biopharma manufacturers The UK is making €15m investment in its biopharmaceutical manufacturing industry via its national innovation agency Innovate UK. It is part of the country’s larger push to support the domestic Life … more ➔
OphtalmologySynbio experts develop cells that hearETH Zurich researchers have developed a gene switch that triggers insulin release in designer cells by playing music. more ➔
CollaborationOxford Biomedica expands agreement with Cabaletta Bio British CDMO Oxford Biomedica plc announces the expansion of its License and Supply Agreement with cell therapy specialist Cabaletta Bio, Inc. The new agreements adds CD19 as a new target – it originally … more ➔
MicrobiologyResearchers decipher mystery of oil-eating microbesOil-eating bacteria form dendritic biofilms that reshape oil droplets to speed up the rate of consumption more ➔
financingValneva announces extension of existing loan agreementFrench vaccine maker Valneva SE will double the amount of a US$100m debt financing granted by Deerfield Management Company and OrbiMed. more ➔
financingSpexis AG bags money for pivotal Phase III trialSwiss Spexis AG has announced a US$2.5m capital commitment to fund a two-part pivotal Phase III study to get market approval for its inhaled cystic fibrosis antibiotic colistimethate sodium. more ➔
M&ANovo Nordisk takes over Inversago Pharma Inc.With a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market. more ➔
